Evaluation of the potential role of a new mutation in mabA in modifying the response of Mycobacterium tuberculosis to isoniazid

Tuberculosis (Edinb). 2013 Nov;93(6):664-7. doi: 10.1016/j.tube.2013.07.003. Epub 2013 Aug 7.

Abstract

A new mutation in mabA, Thr4Ile, was identified in a Mycobacterium tuberculosis isolate from a patient whose culture remained positive after treatment. The same mutation was found in another 5 patients infected by different strains. A putative role for this mutation in the process of diminishing susceptibility to isoniazid is evaluated.

Keywords: Isoniazid; Mutation; Resistance; mabA.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Oxoacyl-(Acyl-Carrier-Protein) Reductase / genetics*
  • 3-Oxoacyl-(Acyl-Carrier-Protein) Reductase / physiology
  • Antitubercular Agents / pharmacology*
  • Antitubercular Agents / therapeutic use
  • Base Sequence
  • Drug Resistance, Bacterial / genetics
  • Humans
  • Isoniazid / pharmacology*
  • Isoniazid / therapeutic use
  • Male
  • Microbial Sensitivity Tests / methods
  • Middle Aged
  • Molecular Sequence Data
  • Mutation*
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / enzymology
  • Mycobacterium tuberculosis / genetics*
  • Sequence Alignment
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / microbiology

Substances

  • Antitubercular Agents
  • 3-Oxoacyl-(Acyl-Carrier-Protein) Reductase
  • Isoniazid